Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis
Key facts
- Who runs it
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 15 people enrolled
- Started
- 19 Jul 2021
- Ended
- 16 Sept 2026
- Type of study
- Interventional
- Treatments tested
- Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
- Record updated
- 22 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patients older than 18 years old
- Chronic rhinosinusitis with Nasal Polyps
- Olfactory loss
- Clinical indication for treatment with Dupilumab
Who cannot take part
- Sinonasal malignancies
- COVID-19 related olfactory loss
- Patients with olfactory loss from other causes such as:
- Trauma
- Idiopathic olfactory loss
- Use of cocaine
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study aims to investigate the olfactory TDI score (Threshold, Discrimination, Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months and 6 months).
Read full original descriptionShow less
The primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders - negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.
The group in the trial
- Dupilumab groupTreatment being tested
Patients with CRSwNP will have an initial dose of 600 mg of dupilumab, and 5 additional doses of 300mg every 4 weeks for 6 months.
Treatment: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The 'Real World' Olfactory Outcomes Treating Nasal Polyposis With Dupilumab
- Record updated
- 22 September 2026